Development of novel devices for assessing drugs promoting neuronal regeneration

开发用于评估促进神经元再生的药物的新型装置

• 批准号: 528835-2018
• 负责人: Juncker, David
• 金额: $ 1.82万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=654930
• 关键词: Development; novel; devices; assessing; drugs

Ananda Devices is a Montreal based SME dedicated to the development and manufacturing of**microfluidic/organ-on-a-chip devices to increase reproducibility and efficiency of cellular assays. Ananda**Devices' proprietary Neuro-MFD offers a more efficient model to test drugs targeting neurodegenerative**diseases in vitro.**Current generation of Neuro-MFD can only test one drug per experiment and larger labs and the**biopharmaceutical industry need to test thousands of drugs. Ananda Devices aims to develop a novel device**(i.e., HT-Neuro-MFD) that can be adapted to automate the drug testing process.**Partnering with Dr. David Juncker to scale the current advantages of the Neuro-MFD to an HT-Neuro-MFD,**Ananda Devices will benefit from scientific, engineering and technical expertise and tools to develop an**innovative product to respond to the market's demand to accelerate drug discovery in neurological diseases.**The activities detailed in this Project will benefit Canada in a variety of ways:**-Technology: The proposed innovative research will train personnel in the areas of bioengineering,**neuroscience, and microfluidic devices to ensure that Canada remains a leader in these cutting-edge fields.**-Export: Over 80% of Ananda Devices's revenue results from export sales, thereby putting Canada at the**forefront of these innovations has the potential to benefit all Canadians economically and advance the output of**Canadian intellectual property.**-Health: The research will ultimately contribute to the development of new drugs that treat neurodegenerative**diseases, such as Parkinson, Alzheimer's, Multiple Sclerosis and ALS.

Ananda Devices是一家总部位于蒙特利尔的中小企业，致力于开发和制造**微流控/单芯片器官设备，以提高细胞分析的重复性和效率。Ananda**Devices的专利Neuro-MFD为在体外测试针对神经退行性疾病的药物提供了一种更有效的模型。**当前一代的Neuro-MFD每次实验只能测试一种药物，更大的实验室和**生物制药行业需要测试数千种药物。阿南达设备公司的目标是开发一种新型设备**(即，HT-Neuro-MFD)，它可以适用于药物测试过程的自动化。**与大卫·容克博士合作，将目前Neuro-MFD的优势扩展到HT-Neuro-MFD，**阿南达设备公司将受益于科学、开发**创新产品，以响应市场加快神经系统疾病药物发现的需求。**本项目中详细说明的活动将以多种方式使加拿大受益：**-技术：拟议的创新研究将培训生物工程、**神经科学和微流体设备领域的人员，以确保加拿大在这些尖端领域保持领先地位。**-出口：阿南达设备公司80%以上的收入来自出口销售。从而使加拿大处于这些创新的前沿，有可能使所有加拿大人在经济上受益，并提高**加拿大知识产权的产出。**-健康：这项研究最终将有助于开发治疗神经退行性疾病的新药，如帕金森、阿尔茨海默氏症、多发性硬化症和肌萎缩侧索硬化症。